Evidence Based Care of Psoriasis

The presentation discusses evidence-based care for psoriasis, focusing on systemic and biologic therapies, leveraging extensive data from clinical trials, including randomized controlled trials and cohort studies. It emphasizes the importance of network meta-analysis for assessing treatment effectiveness, safety, and cost-effectiveness. The speaker highlights the distinctions in patient outcomes, noting that interleukin inhibitors tend to show higher effectiveness and lower discontinuation rates compared to traditional therapies like infliximab. Moreover, real-world data collected through the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) supports the safety profile of these treatments, specifically in relation to serious infections. The talk further explores cost-effectiveness, using pharmacoeconomic models that compare treatment costs against quality-adjusted life years. Discussion includes implications of the Inflation Reduction Act on drug pricing negotiations and the efficacy of biosimilars, with adjustments needed for non-medical switches. Additionally, insights are provided regarding the optimal frequency of lab monitoring, suggesting that infrequent monitoring may be more cost-effective. The talk concludes with a call for continued research in observational data to support treatment decisions and fiscal strategies in healthcare.